COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Marinomed Biotech AG: Publication of a report on the exclusion of subscription rights for a possible second cash capital in-crease of up to 154,053 shares
Marinomed Biotech AG plans a possible second cash capital increase and will publish a report on the exclusion of subscription rights. Negotiations ongoing with investors -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals
Marinomed Biotech AG signs agreement to sell Carragelose business to Unither Pharmaceuticals, facilitating refinancing and focus on Marinosolv. Agreement subject to various conditions
